UK Glioma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Brain and spinal cord tumours called gliomas attack the glial cells in the brain. Positive regulatory environments and the rising prevalence of gliomas are two variables that are expected to drive market expansion. Having a robust pipeline is anticipated to be a key factor in driving the market for glioma therapeutics during the course of the projected period. Over the course of the projected period, it is anticipated that the prevalence of brain tumours would spur market expansion. Global companies in the Glioma Therapeutics Market are Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc, Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Sun Pharmaceutical Industries, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals LLC Ltd., Novartis International AG, Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, Hitachi Medical Corporation.
UK Glioma Therapeutics Market is valued at around $0.13 Bn in 2022 and is projected to reach $0.17 Bn by 2030, exhibiting a CAGR of 3.8% during the forecast period 2023-2030.
The brain and spinal cord can develop gliomas, a specific type of tumour. Gliomas form in the gluey support cells (glial cells), which encircle and support nerve cells.
Glioma frequently exhibits the following signs and symptoms: headache, nausea or vomiting, dizziness or deterioration in mental function, memory loss, urine incontinence, vision issues, speech difficulties, seizures, etc. The market is expected to develop as a result of a number of factors, including the rising prevalence of glioblastoma multiforme, increased R&D, and favourable regulatory environments. During the projected period, a robust pipeline is anticipated to play a significant role in driving the glioblastoma multiforme (GBM) therapy market. The increasing incidence of brain tumours is expected to boost the growth of the market over the forecast period.
Global companies in the Glioma Therapeutics Market are Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc, Taj Pharmaceuticals Limited, Novartis International AG, Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals, LLC, Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, Hitachi Medical Corporation, and others.
Market Drivers
One of the main factors driving the rise in the elderly population is the fact that glioma prevalence rates rise with age, especially between the ages of 45 and 65. The World Health Organization (WHO) predicts a 120 per cent growth in the number of people over 65 from 702.9 million in 2019 to 1,548.9 million in 2050. This increasing rate is alarming because the mortality rate from this illness has sharply increased. Treatments and drugs that increase patient longevity and decrease the incidence of patient fatalities are required as a result of this growth. Rising demand for these drugs is the main reason propelling the worldwide glioma market's revenue growth. One of the main factors driving the rise in the elderly population is the fact that glioma prevalence rates rise with age, especially between the ages of 45 and 65. The World Health Organization (WHO) predicts a 120 per cent growth in the number of people over 65 from 702.9 million in 2019 to 1,548.9 million in 2050. This increasing rate is alarming because the mortality rate from this illness has sharply increased. Treatments and drugs that increase patient longevity and decrease the incidence of patient fatalities are required as a result of this growth. Rising demand for these drugs is the main reason propelling the worldwide glioma market's revenue growth. As the incidence of brain tumours has climbed, so has the need for effective treatment. As a result, international businesses are pouring a sizable portion of their profits into R&D in order to produce cutting-edge drugs.
Market Development
A new, powerful, and selective mutant isocitrate dehydrogenases 1 (mIDH1) inhibitor called safusidenib has demonstrated significant blood-brain barrier permeability. Safusidenib may be a best-in-class treatment for IDH1 mutant lower-grade glioma, according to phase 1 clinical data. For the treatment of recurrent/progressive WHO CNS Grade 2 and Grade 3 IDH1 mutant gliomas, safusidenib is now in Phase II.
High-grade glioma and non-small cell lung cancer are two conditions for which aglatimagene besadenovec is being developed as a therapy. Prostate cancer, advanced non-metastatic pancreatic ductal adenocarcinoma, malignant glioma, paediatric malignant glioma, including glioblastoma multiforme, recurrent glioblastoma multiforme, anaplastic astrocytoma, and recurrent ependymomas.
Chimerix is a biopharmaceutical business on a mission to create drugs that significantly better and prolong the lives of people with life-threatening illnesses. For H3 K27M-mutant glioma, the Company's most advanced clinical-stage development programme, ONC201, is under development.
Market Restraints
Many locals struggle with the big issue of high expenses for anti-cancer treatments. There is intense pressure to reduce costs and demonstrate value. Global political instability and continuous economic stress pose a danger to the sustainability of public healthcare funding. In less developed countries, the lack of accessible drugs has impacted public health and shortened average life expectancy. As a result, pharmaceutical firms are under pressure to reduce global drug prices. Additionally, difficulties with product approval and commercialization, drug side effects, a lack of knowledge and competence about brain cancer and its treatment, and concerns with lack of expertise are all anticipated to significantly hinder market revenue growth.
Key players
Novartis Pfizer AbbVie Johnson & Johnson Amgen Celgene UCB Takeda Pharmaceutical Company Vertex Pharmaceuticals Gilead Sciences1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type of Disease
By Therapy
By diagnosis
By End User
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?